Copy number flexibility facilitates heteroresistance to increasing antibiotic pressure and threatens the beta-lactam pipeline

Jacob E. Choby, Tugba Ozturk, Carter N. Abbott, Christina Nnabuife, Jennifer M. Colquhoun, Sarah W. Satola, Philip N. Rather, Timothy Palzkill and David S. Weiss ()
Additional contact information
Jacob E. Choby: Emory Antibiotic Resistance Center; Emory University School of Medicine
Tugba Ozturk: Emory Antibiotic Resistance Center; Emory University School of Medicine
Carter N. Abbott: Emory Antibiotic Resistance Center; Emory University School of Medicine
Christina Nnabuife: Baylor College of Medicine
Jennifer M. Colquhoun: Emory Antibiotic Resistance Center; Emory University School of Medicine
Sarah W. Satola: Emory Antibiotic Resistance Center; Emory University School of Medicine
Philip N. Rather: Emory Antibiotic Resistance Center; Emory University School of Medicine
Timothy Palzkill: Baylor College of Medicine
David S. Weiss: Emory Antibiotic Resistance Center; Emory University School of Medicine

Nature Communications, 2025, vol. 16, issue 1, 1-17

Abstract: Abstract Our understanding of the rapid adaptation of bacteria to resist novel drugs is growing beyond known mechanisms such as mobile genetic elements and mutation selection. Heteroresistance (HR) is a form of antibiotic resistance where a phenotypically unstable minority resistant subpopulation co-exists with a susceptible population. We sought to uncover the mechanism of heteroresistance to cefiderocol, a novel β-lactam developed to resist β-lactamases including extended-spectrum-β-lactamases (ESBLs), which has been recently reported but poorly understood. We observe HR to cefiderocol among clinical isolates collected before its use. The resistant subpopulation in Enterobacter is a continuum; increasing copy number of a gene encoding an ESBL ineffective against cefiderocol mediates increased resistance in decreasing numbers of cells. We then pursued the factors that control the magnitude of amplification. We observe that ESBL activity correlates with the level of amplification, and thus that increased copy number can compensate for poor enzymatic activity. A Klebsiella isolate from a clinical treatment failure also demonstrates amplification, highlighting the potential relevance of this β-lactamase gene amplification-mediated HR. These data provide insights into factors controlling dynamics of HR and how bacteria can use gene amplification to flexibly confront new antibiotic threats.

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60828-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60828-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60828-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().